GPCR · Structure Therapeutics Inc.

Track GPCR — free

$21.19 -0.74 (-3.37%) At close · Oct 23

Rebalance outlook locked

Market Cap

$1.51B

71.31M

Volume · Oct 23 798.11K Avg daily vol (3M) 1.06M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 122 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$214.84M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$1.34B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+26.2%

Year over year · more shares

Price change (1Y)

-20.2%

Trailing year

Short interest

10.6%

Latest settlement · 5.2 days to cover

View all 122 metrics

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High

Market backdrop VIX 19.5 · elevated Equity put/call 0.67

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −58%

below

Price vs 50-day avg −42%

below

RSI (14) 20

oversold

MACD trend Positive

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −41%

trailing

6-month return −51%

trailing

YTD return −70%

this year

Relative strength −57%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $37 › 200d $50 — 200d above 50d

Institutional flow Distributing

18 of 194 funds reported for Sep 30 · net -45.8K sh shares · +3 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.57% of float · ▲ +14.2% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Squeeze score 53

elevated · 0–100

Fundamentals

Poor

EPS growth −3%

Y/Y

Free cash flow $-225.8M

Quant / Vol

risk profile

Very High

Volatility 119%

annualized · 1-yr

Max drawdown −78%

past year

ATR 7.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−58% Bearish

Price vs 50-day avg

−42% Bearish

RSI (14)

20 Neutral

MACD trend

Positive Bullish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $37 › 200d $50 — 200d above 50d

Institutional flow Distributing

18 of 194 funds reported for Sep 30 · net -45.8K sh shares · +3 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.57% of float · ▲ +14.2% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

194 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $21 Now $21 · 0% Range high $94

vs 200-day avg -58% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GPCR Structure Therapeutics Inc. this stock	$1.51B	-69.5%	—	—	10.6%
VRTX Vertex Pharmaceuticals Inc	$132.80B	+15.6%	+46.2%	30.5	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$82.88B	+4.3%	+20.8%	19.9	2.1%
MRNA Moderna, Inc.	$79.89B	+578.5%	+4.3%	—	7.7%
CSLLY Csl Ltd	$66.42B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

193

% held: 95.5%
Reported: 18 of 194
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

150

View

Short & Settlement

Short Interest Rising

Shares short

7.5M

Days to cover: 5.2d
Change: +935.5K sh

View

Short Volume

Short vol %

37%

As of: Oct 23, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $1.2K
As of: Aug 27, 2026

View

Off-Exchange

Off-exchange %

65.9%

Week of: Sep 14, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Sell

Member

Thomas R Carper

Amount: $1.0K–$15.0K
Traded: Oct 4, 2023

View

Financials

Net income (FY)

$-141.2M

EPS diluted: $-0.80

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 16, 2026
This year: 17

View

Proposed Sales

Value

$140.3K

Shares: 4.0K
Filed: Sep 21, 2026

View

Exempt Offerings

Offering

$7.0M

Filed: Jan 10, 2022

View

Earnings & Events

Webcasts

Last webcast

Sep 16, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
GPCR	+0.5%	-41.0%	-50.8%	-32.2%	-69.5%
SPY	-0.4%	-1.5%	+5.8%	-0.4%	+11.5%
vs SPY	+1.0%	-39.5%	-56.6%	-31.9%	-81.0%

Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 14 filings 14 filers Visit website Investor relations

GPCR · Structure Therapeutics Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance